Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Apatinib as Second-line Treatment of Advanced Pancreatic Cancer (Apslpanc)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02726854
Recruitment Status : Unknown
Verified November 2016 by First Affiliated Hospital Xi'an Jiaotong University.
Recruitment status was:  Recruiting
First Posted : April 4, 2016
Last Update Posted : December 2, 2016
Sponsor:
Information provided by (Responsible Party):
First Affiliated Hospital Xi'an Jiaotong University

Brief Summary:

The main research purpose Evaluation of objective response Apatinib second-line treatment of advanced pancreatic cancer (ORR) and the rate of progression free survival (PFS).

Objective to study the objective and exploratory secondary research To observe the Apatinib in second line treatment of advanced pancreatic cancer disease control rate (DCR), patients with overall survival (OS) benefit, treatment effects on quality of life (QOL) score and drug safety evaluation, To investigate the relationship of apatinib as second-line treatment of advanced pancreatic cancer and the expression of vascular endothelial growth factor receptor(VEGFR) in the serum


Condition or disease Intervention/treatment Phase
Pancreatic Neoplasms Drug: Apatinib Phase 2

Detailed Description:

The purpose of this study is to determine what effects apatinib has on advanced pancreatic cancer patients after failure of first-line chemotherapy cannot tolerate second-line chemotherapy or unwilling to receive second-line chemotherapy of pancreatic cancer patients.To investigate the relationship between apatinib as second-line treatment of advanced pancreatic cancer and the expression of vascular endothelial growth factor receptor(VEGFR) in the serum.

This study choose the First Affiliated Hospital of Xi'an JiaoTong University were unable to tolerate the failure of first-line chemotherapy for second-line chemotherapy or unwilling to receive second-line chemotherapy of pancreatic cancer patients as the research object, the clinical data of clinical subjects age and sex, Eastern Cooperative Oncology Group (ECOG) score, tumor stage, pathological type, pathological grading, giving apatinib treatment, during the treatment of blood monitoring in patients with CA199 levels, imaging findings, assessment of tumor related symptoms and adverse events, and the expression of VEGFR in blood was measured by ELISA method, the curative effect evaluation of the end of the 2 cycle of treatment, patients with effective evaluation to oral apatinib, through the statistical analysis of the data of complete remission (CR) or partial remission (PR), the rate of progression free survival (PFS) expression of CA199 content in serum and serum VEGFR levels of the relevant indicators,. Explore Apatinib for the curative effect and safety of the second-line treatment of advanced pancreatic cancer, and to explore the relationship between the serum VEGF expression level.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Apatinib as Second-line Treatment of Advanced Pancreatic Cancer, Phase II Clinical Study of Open Arm
Study Start Date : April 2016
Estimated Primary Completion Date : December 2017
Estimated Study Completion Date : December 2017

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Apatinib
Patients will be offered with Apatinib (850mg daily,orally)until their disease have progressed.
Drug: Apatinib
Patients with pancreatic cancer who are failed of receiving first-line chemotherapy and cannot tolerate second-line chemotherapy or unwilling to receive second-line chemotherapy will receive Apatinib Tablets (850mg once daily, orally) 30 minutes after meal with warm water. Take 28 days as a cycle, patients will receive this treatment until they have got disease progressed.
Other Name: YN968D1




Primary Outcome Measures :
  1. PFS(Progression free survival) [ Time Frame: 8 Weeks ]
  2. ORR (Objective response rate) [ Time Frame: 8 Weeks ]

Secondary Outcome Measures :
  1. DCR(disease control rate) [ Time Frame: 8 Weeks ]
  2. OS (Overall survival) [ Time Frame: 8 Weeks ]
  3. QoL (Quality of life as assessed by EORTC QLQ-C30) [ Time Frame: 8 Weeks ]
  4. Number of participants with treatment-related adverse events as assessed by NCI-CTC(V3.0) [ Time Frame: 8 Weeks ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • ≥ 18 and ≤ 70 years of age,Male or female;
  • The advanced pancreatic cancer pathology, with measurable lesions (spiral CT scan is more than 10mm, according to the standard of RECIST 1.1);
  • Locally advanced, unresectable recurrent or metastatic pancreatic cancer;
  • According to CTCAE 4.0 and patient complaints, the researchers determine second-line chemotherapy should not be tolerated by the patients or patients want to receive second-line chemotherapy.
  • ECOG performance scale 0-1;
  • Baseline blood routine and biochemical indexes meet the following criteria:

    • Hemoglobin ≥ 80g/L,
    • The absolute neutrophil count (ANC) ≥ 1.5 ×109/L,
    • Blood platelet ≥ 90 ×109/L
    • Alanine aminotransferase(ALT),Aspartate transaminase (AST) less than 2.5 times the upper limit of normal value, equal to or less than 5 times the upper limit of normal (liver metastasis),
    • the serum total bilirubin is less than 1.5 times the upper limit of normal value,
    • Serum creatinine. Less than 1.5 times the upper limit of normal value,
    • Serum albumin is more than 30g/L;
  • Life expectancy ≥ 3 months.
  • women of childbearing age to within 7 days before entering the group of serum or urine pregnancy test and the results were negative. And be willing to give drug test during the test and the last 8 weeks using an appropriate method of contraception. For men, for sterilization, or agreed to during the period of the experiment and at the end of the given experimental drugs for 8 weeks by appropriate methods of contraception;
  • In this study, volunteer subjects signed the informed consent, good compliance with follow-up.

Exclusion Criteria:

  • It is confirmed that of apatinib and / or its accessories allergy;
  • Have high blood pressure and antihypertensive drug treatment can not drop to normal range(systolic pressure >140 mmHg, diastolic blood pressure 90>mmHg), suffering from coronary artery disease above grade I, grade I arrhythmia (including corrected QT interval prolongation male > 450 ms, women > 470 MS) and grade I heart insufficiency; urine protein positive patients.
  • Has a variety of factors influencing oral drugs (such as unable to swallow, nausea, vomiting, chronic diarrhea and intestinal obstruction, etc.);
  • Coagulant function abnormality (INR>1.5, activated partial thromboplastin time(APTT)>1.5, ULN) with bleeding tendency;
  • patients with central nervous system metastasis;
  • pregnant or lactating women;
  • Patients with other malignant tumors within five years;
  • Has a history of psychiatric drugs abuse and can't quit or patients with mental disorders;
  • 4 weeks participated in other clinical trials of patients;
  • received VEGFR inhibitors, such as sorafenib, chougny for treatment;
  • According to the researcher's judgment, there is serious to endanger the safety of patients or affect patients with disease to do the research;
  • The researchers think that the person doesn't fit into.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02726854


Contacts
Layout table for location contacts
Contact: Danfeng Dong, MD 008615349257340 qiwudanfeng@sina.com

Locations
Layout table for location information
China, Shaanxi
First affiliate hospital of Xi'an Jiaotong University Recruiting
Xi'an, Shaanxi, China, 710061
Contact    2982655038      
Contact: , China    2982655038      
Sponsors and Collaborators
First Affiliated Hospital Xi'an Jiaotong University
Investigators
Layout table for investigator information
Study Chair: Enxiao Li, MD First Affiliated Hospital Xi'an Jiaotong University

Layout table for additonal information
Responsible Party: First Affiliated Hospital Xi'an Jiaotong University
ClinicalTrials.gov Identifier: NCT02726854     History of Changes
Other Study ID Numbers: XJTU1AF-CRF-2015-024
First Posted: April 4, 2016    Key Record Dates
Last Update Posted: December 2, 2016
Last Verified: November 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Additional relevant MeSH terms:
Layout table for MeSH terms
Pancreatic Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Endocrine Gland Neoplasms
Pancreatic Diseases
Digestive System Diseases
Endocrine System Diseases
Apatinib
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action